JB Pharma reported a 19% net profit rise to ₹207.8 crore, driven by strong domestic sales of Cilacar, Metrogyl, Nicardia, Sporlac, and Razel, with international revenue up 7%. The shares of JB Pharma ended 0.7% in the green on Tuesday, November 11.
JB Pharma reported a 19% net profit rise to ₹207.8 crore, driven by strong domestic sales of Cilacar, Metrogyl, Nicardia, Sporlac, and Razel, with international revenue up 7%. The shares of JB Pharma ended 0.7% in the green on Tuesday, November 11.